{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:42:46Z","timestamp":1792611766137,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102542","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T05:54:28Z","timestamp":1601358868000},"page":"102542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-373X","authenticated-orcid":false,"given":"Wenjuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzi","family":"ZhangBao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan K.","family":"Behne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta M.","family":"Behne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Yeaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanzhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102542_bib0001","article-title":"Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"4","author":"Asseyer","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"4","key":"10.1016\/j.msard.2020.102542_bib0002","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2020.102542_bib0003","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/WNO.0000000000000403","article-title":"Neuromyelitis optica spectrum disorder: disease course and long-term visual outcome","volume":"36","author":"Brody","year":"2016","journal-title":"J. Neuroophthalmol."},{"issue":"3","key":"10.1016\/j.msard.2020.102542_bib0004","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.autrev.2018.01.001","article-title":"Diagnosis and management of neuromyelitis optica spectrum disorders - An update","volume":"17","author":"Bruscolini","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"8","key":"10.1016\/j.msard.2020.102542_bib0005","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","article-title":"Incidence and prevalence of NMOSD in Australia and New Zealand","volume":"88","author":"Bukhari","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102542_bib0006","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1212\/NXI.0000000000000286","article-title":"Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder","volume":"3","author":"Chavarro","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2020.102542_bib0007","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1177\/1363461509351374","article-title":"Why do Chinese Canadians not consult mental health services: health status, language or culture?","volume":"46","author":"Chen","year":"2009","journal-title":"Transcult. Psychiatry"},{"key":"10.1016\/j.msard.2020.102542_bib0008","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1212\/NXI.0000000000000583","article-title":"Collaborative international research in clinical and longitudinal experience study in NMOSD","volume":"6","author":"Cook","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"10206","key":"10.1016\/j.msard.2020.102542_bib0009","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.msard.2020.102542_bib0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2020.102542_bib0011","first-page":"375","article-title":"Reliability and validity of Chinese version of the multiple sclerosis quality of life-54 questionnaire","volume":"4","author":"Kang","year":"2009","journal-title":"Chin. J. Behav. Med. Brain. Sci."},{"issue":"1","key":"10.1016\/j.msard.2020.102542_bib0012","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.msard.2020.102542_bib0013","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1167\/iovs.06-0361","article-title":"The impact of vision impairment questionnaire: an assessment of its domain structure using confirmatory factor analysis and rasch analysis","volume":"48","author":"Lamoureux","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9451","key":"10.1016\/j.msard.2020.102542_bib0014","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102542_bib0015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/jnnp-2017-317566","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorders","volume":"89","author":"Mori","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102542_bib0016","unstructured":"National Bureau of Statistics China, 2010. Tabulation on the 2010 population census of the People's Republic of China. http:\/\/www.stats.gov.cn\/tjsj\/pcsj\/rkpc\/6rp\/indexch.htm(Accessed March 23, 2020)."},{"key":"10.1016\/j.msard.2020.102542_bib0017","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1037\/0022-3514.91.4.730","article-title":"Psychological resilience, positive emotions, and successful adaptation to stress in later life","volume":"91","author":"Ong","year":"2006","journal-title":"J. Personal. Soc. Psych."},{"issue":"5","key":"10.1016\/j.msard.2020.102542_bib0018","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102542_bib0019","first-page":"636","article-title":"Survey of health-related quality of life in population of 6 Chinese cities","volume":"31","author":"Pan","year":"2011","journal-title":"Basic Clin. Med."},{"issue":"24","key":"10.1016\/j.msard.2020.102542_bib0020","doi-asserted-by":"crossref","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"issue":"10063","key":"10.1016\/j.msard.2020.102542_bib0021","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1016\/S0140-6736(16)00160-4","article-title":"The magnitude of and health system responses to the mental health treatment gap in adults in India and China","volume":"388","author":"Patel","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.msard.2020.102542_bib0022","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2020.102542_bib0023","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/BOR.0000000000000603","article-title":"Treatment of neuromyelitis optica spectrum disorders","volume":"31","author":"Romeo","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.msard.2020.102542_bib0024","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.msard.2016.11.008","article-title":"Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders","volume":"11","author":"Schmidt","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102542_bib0025","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2020.102542_bib0026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102542_bib0027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Qual. Life Res."},{"issue":"11","key":"10.1016\/j.msard.2020.102542_bib0028","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/1352458518792430","article-title":"A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia","volume":"25","author":"Viswanathan","year":"2019","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2020.102542_bib0029","first-page":"927","article-title":"Assessment of the impact of vision impairment","volume":"43","author":"Weih","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.msard.2020.102542_bib0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.msard.2020.102542_bib0031","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2020.102542_bib0032","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102542_bib0033","first-page":"1","article-title":"Anxiety- and health-related quality of life among patients with breast cancer: a cross-cultural comparison of china and the United States","volume":"4","author":"You","year":"2018","journal-title":"J. Glob. Oncol."},{"key":"10.1016\/j.msard.2020.102542_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577093","article-title":"Sexual dysfunction in patients with neuromyelitis optica spectrum disorder","volume":"338","author":"Zhang","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102542_bib0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jneuroim.2016.11.010","article-title":"The clinical characteristics of AQP4 antibody positive NMO\/SD in a large cohort of Chinese Han patients","volume":"302","author":"ZhangBao","year":"2017","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:00Z","timestamp":1761900600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820306167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":35,"alternative-id":["S2211034820306167"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102542","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102542"}}